How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes?

Diabetes Care ◽  
1999 ◽  
Vol 22 (6) ◽  
pp. 904-907 ◽  
Author(s):  
M. Bouma ◽  
J. H. Dekker ◽  
J. J. de Sonnaville ◽  
F. E. van der Does ◽  
H. de Vries ◽  
...  
1970 ◽  
Vol 19 (4) ◽  
pp. 2819-2828
Author(s):  
Innocent Chidi Anioke ◽  
Azubike Nnamdi Ezedigboh ◽  
Ogechukwu Calista Dozie-Nwakile ◽  
Ikechukwu Johnpaul Chukwu ◽  
Peculiar Ngozi Kalu

Background: The study investigated predictors of poor glycemic control in type 2 diabetes (T2DM).Methods: Data on demographics, anthropometric and clinical parameters were collected in a cross-section survey from 140 adults with T2DM, using standard tools/instruments. Glycated hemoglobin (A1C) was assessed as a measure of glycemic control. Results: Majority (83.3%) had poor glycemic control status of which about 95% constitute the elderly. The elderly (OR= 5.90, 95% Cl: 1.66-20.96) were more likely associated with poor glycemic control than the non-elderly (p = 0.006). Adjustment for significant predictor variables: Age, waist-hip ratio (WHR), Fasting plasma glucose (FPG) and Systolic blood pressure (SBP), although attenuated the odds (OR= 5.00, 95% CI: 1.19-20.96) of poor glycemic control, it still remained significantly (p = 0.028) higher in the elderly. Patients outside tight FPG control significantly (p = 0.001) showed poor glycemic cotrol than those within tight FPG (OR= 17.39, 95%Cl: 5.83-51.90), even with attenuated OR (OR= 10.85, 95%Cl: 3.10-37.96) and (OR=12.08, 95%Cl: 3.64-40.09) when non- significant and significant predictor variables were accounted for, respectively.Conclusion: Age, WHR, FPG, and SBP were significantly associated with differences in glycemic control. The elderly and FPG outside tight control showed significantly increased odds of poor glycemic control status.Keywords: Type 2 Diabetes Mellitus; glycemic control status; A1C; Elderly; Fasting plasma glucose; glycemic control predictors.


2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A471-A471
Author(s):  
Felipe Rodrigues Lima Mágero ◽  
Larissa Frazao Vasconcellos ◽  
Larissa Frazão ◽  
Francisco Bandeira

Abstract Introduction: Irisin is a newly discovered myokine whose expression is induced by exercise and PGC1α. Studies have reported its action on adipose tissue cells, leading to their “browning,” and consequent increase in energy expenditure and thermogenesis. In the first description of this hormone, which is a product of cleavage of its precursor (protein 5 containing fibronectin type III domain), elevated irisin levels were associated with improved insulin sensitivity, weight reduction, and better glucose tolerance in animal models. Hence, studies have tried to characterize the role of irisin in glucose regulation, with controversial results. Muscle mass has been a good predictor of irisin circulation in humans and, because it is predominantly synthesized and secreted by skeletal muscle, its use as a potential biomarker of sarcopenia has been investigated. Methods: The aim of this study was to evaluate serum FNDC5 levels according to clinical and metabolic parameters as well as muscle mass from patients with type 2 diabetes (T2DM). Body composition was evaluated by Dual X-ray absortptiometry (DXA) and multifrequency Bioelectric Impedance (BIA) and FNDC5 was measured using an ELISA kit. Results: We evaluated 44 women with type-2 diabetes, mean age of 61.95±8.52 years, mean diabetes duration of 10.25±7.06 years, mean HbA1c of 7.66±1.37, mean fasting plasma glucose of 149.11±38.26 mg/dL, mean BMI of 29.20±5.15 kg/m2, and mean abdominal circumference of 95.02±12.80 cm. Mean FNDC5/irisin was 18.69±3.67 ng/mL. Although there were no differences in DXA and BIA analyses according to first and top quartiles of serum FNDC5, we identified a negative correlation of serum FNDC5 with fasting plasma glucose (−0.479; P=0.001) and a positive correlation with age (0.422; P=0.004). Conclusion: our data demonstrated that increased serum FNDC5 is related to increased age and poor glycemic control in T2DM. Reference: (1) Perakakis N et al., Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017 (2) Hyun HP et al., The novel myokine irisin:clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women. Endocrine. 2018.


2003 ◽  
Vol 88 (8) ◽  
pp. 3598-3604 ◽  
Author(s):  
Alan J. Garber ◽  
Daniel S. Donovan ◽  
Paresh Dandona ◽  
Simon Bruce ◽  
Jong-Soon Park

Many patients with type 2 diabetes fail to achieve or maintain the American Diabetes Association’s recommended treatment goal of glycosylated hemoglobin levels. This multicenter, double-blind trial enrolled patients with type 2 diabetes who had inadequate glycemic control [glycosylated hemoglobin A1C (A1C), >7% and <12%) with diet and exercise alone to compare the benefits of initial therapy with glyburide/metformin tablets vs. metformin or glyburide monotherapy. Patients (n = 486) were randomized to receive glyburide/metformin tablets (1.25/250 mg), metformin (500 mg), or glyburide (2.5 mg). Changes in A1C, fasting plasma glucose, fructosamine, serum lipids, body weight, and 2-h postprandial glucose after a standardized meal were assessed after 16 wk of treatment. Glyburide/metformin tablets caused a superior mean reduction in A1C from baseline (−2.27%) vs. metformin (−1.53%) and glyburide (−1.90%) monotherapy (P = 0.0003). Glyburide/metformin also significantly reduced fasting plasma glucose and 2-h postprandial glucose values compared with either monotherapy. The final mean doses of glyburide/metformin (3.7/735 mg) were lower than those of metformin (1796 mg) and glyburide (7.6 mg). First-line treatment with glyburide/metformin tablets provided superior glycemic control over component monotherapy, allowing more patients to achieve American Diabetes Association treatment goals with lower component doses in drug-naive patients with type 2 diabetes.


Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 1006-P
Author(s):  
AOIFE M. EGAN ◽  
CHRISTINA WOOD-WENTZ ◽  
KENT R. BAILEY ◽  
ADRIAN VELLA

Sign in / Sign up

Export Citation Format

Share Document